I’ve been preaching a bit on this blog about how we have to try to use new digital technologies in healthcare marketing (particularly pharma) . I’ve also tried to show that it is possible to do use these technologies in a regulatory compliant way…at least for some things.
But I’ve realized one thing lately. Yes, there are a lot of companies whose internal processes or culture make it extremely difficult to try out some of these new ideas. I’ve considered this situation and the lack of willingness to break this trend to be the fault of healthcare marketers. However, I realize that I may have been too harsh. In fact, they share the blame.
This is a teaser of FDA Isn’t Ready For Us…Stop All E-Marketing!
. Click here to read the full post: (1084 words, ~4:20 minutes reading time)
Sure, the title of this is supposed to be a little provocative, but isn’t that the point? I’m taking a cue from the source of this information after all (read on, you’ll see). Recently, Pharmaceutical Executive published a report on a recent Manhattan Research study (press release here) looking at the use of online social networking sites by physicians. There’s already been some good debate about this article on several blogs, so I won’t rehash the same things, but rather I’d like to just correct some of the misconceptions of the study.
This is a teaser of Social Networking Doctors Overprescribe
. Click here to read the full post: (821 words, ~3:17 minutes reading time)
I’ve written a fair amount about the use of social media in healthcare (here and here), particularly pharma, on this blog. And, like many other people working to try to enhance healthcare marketing by including channels such as social media, I’ve heard all the same excuses. I was reading John Mack’s post today at Pharma Marketing Blog and it inspired me to write a quick little summary about what I call “The Myth of Adverse Event Reporting.”
This is a teaser of The Myth of Adverse Event Reporting
. Click here to read the full post: (1463 words, 2 images, ~5:51 minutes reading time)
Pharma in the US has had a rough go over the past several years getting crushed by bad PR, new legislation, and a few monster fines. Of course, a lot of it the industry brought upon itself, but some is owed to the fact that nothing is more regulated than prescription drugs in the United States (perhaps plutonium is slightly more regulated, but not much). This regulation is partly where pharma places blame for slumping sales. They argue that their hands are tied and that’s it’s extremely difficult to get the word out about the benefits of new and existing products (or to simply get them approved). Of course, it is easier in the US than pretty much anywhere (except New Zealand), as the US does have the benefit of being allowed to do DTC advertising. Imagine what it would be like without that. Not that bad, right? Maybe, maybe not.
This is a teaser of US Pharma Can’t Win (Awards that Is)
. Click here to read the full post: (871 words, 1 image, ~3:29 minutes reading time)
